Therapeutics case studies

A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted ICON to
support patient enrollment.

Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.

ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.

A biotechnology company, dedicated to transforming Women’s Health, was running a phase 3 study in the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women with a global enrollment target of 1,200 patients.

Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.

A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.

Four studies were awarded by a pharma organisation over a period of less than two years, with overlapping
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.

Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.

A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.

One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.

ICON’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.

A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. ICON was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.